Is NCT07323654 recruiting in Redding, CA?

Yes, NCT07323654 is currently recruiting participants at its Redding, CA location. This eosinophilic asthma clinical trial is actively enrolling qualified participants.

How do I join the eosinophilic asthma clinical trial in Redding?

To join this clinical trial in Redding, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Redding clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Eosinophilic Asthma Clinical Trial in Redding, CA

About This Eosinophilic Asthma Study in Redding

This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.

Sponsor: Kymera Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Must be 18 years old (or the legal age of consent in the jurisdiction in which the study is taking place) to 75 years of age, inclusive, at the time of signing the ICF.

Must have a physician diagnosis of asthma for at least 1 year prior to the Screening visit.

Must be on a stable regimen of medium- to high- dose inhaled corticosteroid (ICS), in combination with a long-acting β2-agonist (LABA). The regimen may include additional controller medications used for at least 12 weeks, at a stable dose and regimen, with no change in the dose or frequency of administration for at least 4 weeks prior to the Screening visit and between the Screening and Baseline visits.

Must have a pre-bronchodilator FEV1 40 to 80% of predicted normal at the Screening and Baseline visits, prior to randomization.

Must have an ACQ-5 score ≥ 1.5 at the Screening and Baseline visits, prior to randomization.

Must have a FeNO level of ≥ 25 ppb at the Screening and Baseline visits.

Must have a demonstrated evidence of reversible airway obstruction by post-bronchodilator (albuterol/salbutamol) reversibility of FEV1 ≥12% and ≥200 mL at Screening.

Must have an absolute blood eosinophil count must be ≥ 0.30 × 10\^9/L at Screening.

Must have a documented history of at least 1 asthma exacerbation requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and/or hospitalization or an emergency/urgent medical care visit for acute asthma worsening within the past 52 weeks prior to Screening.

Must agree to contraceptive requirements in compliance with the clinical study and local requirements.

Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.

Exclusion Criteria

Must not have any clinically significant pulmonary disease other than asthma.

Must not have had an asthma exacerbation, requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and/or hospitalization or an emergency/urgent medical care visit for acute asthma worsening, at any time from 4 weeks prior to the Screening visit up to and including the Baseline visit.

Must not have any other clinically significant disease, condition, or medical history that, in the opinion of the Investigator, would interfere with participant safety, study evaluations, and/or study procedures.

Must not be pregnant or breastfeeding; must not be a woman planning to become pregnant or breastfeed during the study.

Must not have results from clinical laboratory safety tests that are outside the local reference range at Screening.

Must not have been dosed with any investigational drug or device in a clinical study within 8 weeks or 5 half-lives (whichever is longer) of KT-621 administration.

Must not have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results.

Must not be a current smoker of nicotine/tobacco as well as non-nicotine products, have a smoking history of ≥ 10 pack years, or use vaping products, including electronic cigarettes. Former smokers with a smoking history of \< 10 pack years and users of vaping or e-cigarette products must have stopped for at least 26 weeks prior to the Screening visit.

Must not have a known sensitivity to any of the components of KT-621.

Must not be a member of the investigational team or his/her immediate family.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Redding?

Yes, this clinical trial (NCT07323654) has an active research site in Redding, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Eosinophilic Asthma Treatment Options in Redding, CA

If you're searching for eosinophilic asthma treatment options in Redding, CA, this clinical trial (NCT07323654) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Redding research site is actively enrolling participants for this clinical trial. You'll receive care from experienced eosinophilic asthma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all eosinophilic asthma clinical trials near you to find additional studies recruiting in your area.

Eosinophilic Asthma Clinical Trial in Redding, CA

Expert Care in Redding

IRB Approved

No-Cost Care

Apply for This Redding Location

Why Participate?

Simple Process